Parathyroid hormone and large related C-terminal fragments increase at different rates with worsening of renal function in chronic kidney disease patients. A possible indicator of bone turnover status?

2007 ◽  
Vol 67 (03) ◽  
pp. 131-139 ◽  
Author(s):  
C. Donadio ◽  
M. Ardini ◽  
A. Lucchesi ◽  
E. Donadio ◽  
T. Cantor
Keyword(s):  
Chronic Kidney Disease ◽  
Renal Function ◽  
Parathyroid Hormone ◽  
Kidney Disease ◽  
Bone Turnover

Iron-based phosphorus chelator: Risk of iron deposition and action on bone metabolism in uremic rats

2021 ◽  
pp. 153537022110572
Author(s):  
Wander Barros do Carmo ◽  
Bárbara Bruna Abreu Castro ◽  
Luísa Cardoso Manso ◽  
Priscylla Aparecida Vieira do Carmo ◽  
Clóvis Antônio Rodrigues ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Renal Function ◽  
Parathyroid Hormone ◽  
Calcium Carbonate ◽  
Kidney Disease ◽  
Therapeutic Option ◽  
Fractional Excretion ◽  
Control Group ◽  
Clinical Settings ◽  
Iron Based

Phosphate chelators are frequently used in patients with chronic kidney disease (CKD). New iron-based chelators remain understudied and offer a promising therapeutic option for the control of bone and mineral disorders of chronic kidney disease (BMD-CKD). We assessed the effect of the phosphorus chelator, chitosan-iron III (CH-FeCl), compared to calcium carbonate (CaCO3) in BMD-CKD and the potential iron overload in uremic rats. Thirty-two animals were divided into four groups, namely the control, CKD, CKD/CH-FeCl, and CKD/CaCO3 groups. CKD was induced by adding 0.75% (4 weeks) and 0.1% (3 weeks) adenine to the diet. The chelators were administered from week 3 through week 7. The renal function, BMD-CKD markers, and histomorphometry of the femur were assessed at week 7. The CKD group showed a significant increase in creatinine (83.9 ± 18.6 vs. 41.5 ± 22.1 µmol/L; P = 0.001), phosphate (3.5 ± 0.8 vs. 2.2 ± 0.2 mmol/L; P = 0.001), fractional excretion of phosphorus (FEP) (0.71 ± 0.2 vs. 0.2 ± 0.17; P = 0.0001), and FGF23 (81.36 ± 37.16 pg/mL vs. 7.42 ± 1.96; P = 0.011) compared to the control group. There was no accumulation of serum or bone iron after the use of CH-FeCl. The use of chelators reduced the FEP (control: 0.71 ± 0.20; CKD/CH-FeCl: 0.40 ± 0.16; CKD/CaCO3 0.34 ± 0.15; P = 0.001), without changes in the serum FGF23 and parathyroid hormone levels. Histomorphometry revealed the presence of bone disease with high remodeling in the uremic animals without changes with the use of chelators. The CH-FeCl chelator was efficient in reducing the FEP without iron accumulation, thereby paving the way for the use of this class of chelators in clinical settings in the future.

Non-oxidized parathyroid hormone (PTH) measured by current method is not superior to total PTH in assessing bone turnover in chronic kidney disease.

2021 ◽  
Author(s):  
Stan R. Ursem ◽  
Annemieke C. Heijboer ◽  
Patrick C. D’Haese ◽  
Geert J. Behets ◽  
Etienne Cavalier ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Parathyroid Hormone ◽  
Kidney Disease ◽  
Bone Turnover ◽  
Current Method

EFFECTIVENESS OF ANTIAGGREGANT THERAPY ON KIDNEY ACTIVITY IN THE PREDIALYSIS STAGE OF CHRONIC KIDNEY DISEASE

2020 ◽  
Vol 6 (1) ◽  
pp. 55-60
Author(s):  
Khabib Barnoev ◽  
◽  
Sherali Toshpulatov ◽  
Nozima Babajanova ◽  
Keyword(s):  
Chronic Kidney Disease ◽  
Renal Function ◽  
Kidney Disease ◽  
Comparative Study ◽  
Functional Status ◽  
Stage Ii ◽  
Term Administration ◽  
Antiaggregant Therapy

The article presents the results of a study to evaluate the effectiveness of antiaggregant therapy on the functional status of the kidneys in 115 patients with stage II and III chronic kidney disease on the basis of a comparative study of dipyridamole and allthrombosepin. Studies have shown that long-term administration of allthrombosepin to patients has led to improved renal function.

Sign in / Sign up

Export Citation Format

Share Document